4 Spam-Free Article(s) Found
Sort:
Like
Filter:
7d
Article Searches
Teva Pharmaceutical Industries: Potential Outweighs Concerns https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
Teva stock trades in the green for seventh straight session https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_sector_healthcare Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567 Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405 Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

Pages: 1

Page 1